April 20, 2016

Research shines new light on malignant hyperthermia

By: OR Manager
Share

The rare but very serious condition of malignant hyperthermia (MH) remains a risk at all surgical facilities, including ambulatory surgical centers (ASCs). MH occurs in about one in 50,000 adults under anesthesia, and one in about 12,000 children, which translates to one or two deaths annually in the United States. When it does strike, MH often is fatal if not treated within minutes. And the only antidote is a very expensive drug.

Welcome to OR Manager, your source of information and insight into the clinical and business management of the surgical suite. This article is only available to OR Manager subscribers. To read this article, and gain access to all OR Manager resources, please log in below:

LOGIN
  Join the OR Manager Community! OR Manager is the trusted source for perioperative leaders, providing critical information, analysis, and best practices for management of the surgical suite. Join as a Premium Subscriber to access all articles online including archives, the digital issue of OR Manager each month, eligibility for CE contact hours, registration discounts on conferences and more. We also offer a complimentary Plus subscription to those who qualify and a complimentary Community subscription.

Explore Subscription Options

Please contact our Customer Service Team if you are unable to log in at [email protected] or 1-888-707-5814.

Live chat by BoldChat